Phase 3 trials support expanded use of Dysport for migraine prevention
pharmafile | July 15, 2026 | News story | Research and Development | Dysport, ipsen, migraine prevention
Ipsen has reported positive topline results from its phase 3 BEOND clinical programme evaluating Dysport (abobotulinumtoxinA) for the prevention of both episodic and chronic migraine in adults.
Both the E-BEOND and C-BEOND studies met their primary endpoints, demonstrating a reduction in monthly migraine days compared with placebo.
Migraines affects around 14% of the global population and can have a significant impact on patients’ ability to work, socialise and carry out everyday activities. While several preventive treatments are available, many patients continue to experience frequent or debilitating attacks.
According to Ipsen, the results mark the first phase 3 programme to demonstrate the efficacy of a botulinum toxin in preventing both episodic and chronic migraine. The E-BEOND trial also represents the first phase 3 study to show statistically significant efficacy for a botulinum toxin in episodic migraine.
Christelle Huguet, Executive Vice President and Global Head of R&D at Ipsen, said that the results represented a “significant” advance in the development of botulinum toxin therapies for migraines.
She added: “BEOND is the first phase 3 programme to demonstrate efficacy of a botulinum toxin in both episodic and chronic migraine. Together, these findings position Dysport as a potential first-in-class treatment for a broad migraine population.”
Dysport was generally well tolerated across both studies, with no new or unexpected safety signals identified.
Jessica Ailani, Clinical Professor of Neurology at MedStar Georgetown University Hospital and Principal Investigator for the E-BEOND trial, said the findings were encouraging as they suggested a potential new preventive treatment option for a broad group of patients if approved.
Ipsen said detailed findings from the programme will be presented at a future scientific congress.
Related Content
Ipsen’s Iqirvo approved for use in NHS Scotland to treat rare liver disease
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsen’s Iqirvo (elafibranor) in NHS …
FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental …
Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment
Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the …
